Recursion Pharmaceuticals, Inc.
3.215USD
-0.2250 (-6.54%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 6 | 36 | 5 | 19 | 15 | 5 | 26 |
| Cost of Revenue | 11 | 12 | 14 | 15 | 20 | 22 | 13 | 12 |
| Gross Profit | -4 | -6 | 21 | -10 | -1 | -7 | -8 | 14 |
| Operating Income | -135 | -129 | -108 | -172 | -176 | -191 | -184 | -98 |
| Net Income | -131 | -118 | -108 | -162 | -172 | -202 | -179 | -96 |
| EPS (Diluted) | $-0.25 | $-0.22 | $-0.17 | $-0.36 | $-0.41 | $-0.50 | $-0.57 | $-0.34 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)